Apogee Therapeutics: Targeting Atopic Dermatitis

2026-05-21 11:53:46 ET

Shares of inflammatory and immunology concern Apogee Therapeutics, Inc. ( APGE ) have roughly doubled since October 2025 as the lead asset zumilokibart continues its trend towards best-in-class. To date, the much less frequent maintenance dosing candidate for atopic dermatitis matched or bettered approved therapies with more frequent dosing schedules on multiple measures. With a valuation of $4.8 billion net of cash, a pivotal atopic dermatitis trial expected to start this year, and pipeline-in-a-product expectations for zumilokibart, Apogee’s rally merited a deeper dive. An analysis follows below....

Read the full article on Seeking Alpha

For further details see: